Successful Management of Lupus‐Associated Autoimmune Myelofibrosis with Tofacitinib: A Case Report
We report a case of a 34-year-old woman with systemic lupus erythematosus (SLE) who developed thrombocytopenia and was diagnosed with lupus-associated autoimmune myelofibrosis. She was treated with hydroxychloroquine, tofacitinib (5 mg twice daily), intravenous Ig, and prednisone (5 mg twice daily, tapered to 5 mg daily after one month). After 10 months of this regimen, her bone marrow showed complete resolution of myelofibrosis. This case highlights the effectiveness of tofacitinib in the treatment of autoimmune myelofibrosis associated with SLE.
Authors
- Hamidreza Soltani (ORCID: https://orcid.org/0000-0003-1165-7676)
- Ali Dehghan (ORCID: https://orcid.org/0000-0001-9291-6419)
Institutions
- Shahid Sadoughi University of Medical Sciences and Health Services (IR)
Publication Details
- Journal
- ACR Open Rheumatology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/acr2.70017
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00